# Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

> **NCT04009109** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Alliance Foundation Trials, LLC.** · enrollment: 79 (actual)

## Conditions studied

- Myeloma, Multiple

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Ixazomib
- **DRUG:** Daratumumab Injection
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04009109
- **Lead sponsor:** Alliance Foundation Trials, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-21
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04009109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04009109, "Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04009109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*